Suzhou Zelun New Drug Research and Development

Suzhou Zelun New Drug Research and Development is a biopharmaceutical company based in Suzhou, China, and a key R&D subsidiary of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. The company focuses on the discovery and development of innovative small molecule drugs, particularly in the fields of oncology and autoimmune diseases. Its lead candidate, YS001, is a dual PI3K/mTOR inhibitor currently in Phase 1 clinical trials for advanced malignant solid tumors. Suzhou Zelun leverages its parent company's integrated platform for drug discovery, clinical development, and manufacturing to advance its pipeline of novel therapeutics. The company is part of a broader strategic initiative by Jiangsu Wuzhong to transition from a traditional pharmaceutical manufacturer to an innovation-driven biotech player.